MEKTOVI (binimetinib)

MEKTOVI (binimetinib)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

• Indicated in combination with Braftovi™ (encorafenib capsules), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA approved test.

The following criteria must be met:

• Medication is prescribed by or in consultation with an oncologist, AND
• Patient has unresectable, advanced, or metastatic melanoma, AND
• Patient has melanoma with BRAF V600 mutation, AND
• Mektovi will be used in combination with Braftovi™ (encorafenib capsules)

Dosing:

• 45 mg orally taken twice daily in combination with encorafenib until disease progression or unacceptable toxicity.

Approval:

1 year